Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) is now available.
Beijing Biostar Pharmaceuticals Co., Ltd. has announced its Annual General Meeting (AGM) scheduled for August 25, 2025, where key resolutions will be discussed. These include approving the financial statements and reports for 2024, determining remuneration packages for directors and supervisors, and appointing a new auditor. Additionally, a special resolution will be considered to authorize the repurchase of up to 10% of the company’s H Shares, reflecting strategic financial management and potential implications for capital market positioning.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on the development and production of biological and chemical drugs, targeting various market segments within the healthcare sector.
Average Trading Volume: 1,140,900
Technical Sentiment Signal: Hold
Find detailed analytics on 2563 stock on TipRanks’ Stock Analysis page.